Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Tables)

v3.24.1.1.u2
Notes Payable (Tables)
3 Months Ended
Mar. 31, 2024
Notes Payable  
Schedule of Notes Payable

 

    March 31,     December 31,  
    2024     2023  
On March 4, 2024, the Company completed the sale of a promissory note to the Sanguine Group, LLC (“Sanguine”) in the principal amount of $360,000 for a net purchase price of $300,000 after deduction of a $60,000 Original Issue Discount that is being amortized over the life of the loan, pursuant to a securities purchase agreement between the Company and Sanguine. The Note matures on September 4, 2024, and bears interest at a rate of 15% per annum, calculated based on a 360-day year. The Company also paid $15,000 of legal fees and a commitment fee in the form of 2,500,000 shares of common stock, as noted, below. The proceeds were used to repay the Third AJB Note in the principal amount of $300,000. The promissory note was repaid on April 22, 2024 out of proceeds received from debt financing received by SDT Equities LLC.
 
Pursuant to the Purchase Agreement, the Company paid a commitment fee to Sanguine in the form of 2,500,000 shares of the Company’s common stock (the “Commitment Fee Shares”). The Commitment Fee Shares resulted in a debt discount of $73,454 that is being amortized over the life of the loan.
  $ 360,000     $ -  
                 
On August 18, 2023, the Company, through its wholly-owned subsidiary, OWP Ventures, Inc., issued an unsecured promissory note of $35,000 to LDL8 Consulting, LLC for the purchase of equipment from another vendor. The promissory note bears interest at 10% per annum and is due on demand. In the event of default, the interest rate increases to 15% until repayment.     35,000       35,000  
                 

On June 23, 2023, the Company completed the sale of a Promissory Note in the principal amount of $300,000 (the “Third AJB Note”) to AJB Capital Investments LLC (“AJB Capital”) for an aggregate purchase price of $276,000, pursuant to a Securities Purchase Agreement between the Company and AJB Capital (the “Purchase Agreement”). The Company received net proceeds of $262,500 after deduction of an original issue discount of $24,000, $7,500 of legal fees and a $6,000 of broker fee, which were amortized as a debt discount over the life of the loan.

 

The Third AJB Note matured on March 23, 2024 (the “Maturity Date”), carried interest at a rate of 12% per annum, and, following an event of default only, was convertible into shares of the Company’s common stock at a conversion price equal to the lesser of the Volume Weighted Average Price (“VWAP”) during (i) the 10-trading day period preceding the issuance date of the note, or (ii) the 10-trading day period preceding date of conversion of the Note. The Note was also subject to covenants, events of defaults, penalties, default interest and other terms and conditions customary in transactions of this nature.

 

Pursuant to the Purchase Agreement, the Company paid a commitment fee to AJB Capital in the amount of $100,000 (the “Commitment Fee”) in the form of 1,666,667 shares of the Company’s common stock (the “Commitment Fee Shares”). During the period commencing on the six-month anniversary of the closing date and ending on the five-year anniversary of the closing date, AJB Capital is entitled to be issued additional shares of common stock or receive a cash payment to the extent AJB Capital’s sale of the Commitment Fee Shares has resulted in net proceeds in an amount less than the Commitment Fee. The Commitment Fee Shares resulted in a debt discount of $42,175 that was amortized over the life of the loan.

 

In connection with the issuance of the Third AJB Note and Commitment Fee Shares, the Company entered into a Registration Rights Agreement with AJB Capital in which the Company agreed to file a registration statement with the SEC within 180 days of June 23, 2023, registering the shares of common stock issuable under the Third AJB Note and Purchase Agreement. The note was repaid on March 14, 2024 out of the proceeds received from the Sanguine Group Note.

    -       300,000  
                 
Total notes payable     395,000       335,000  
Less: unamortized debt discounts     126,670       24,136  
Notes payable, net of discounts     268,330       310,864  
Less: current maturities     268,330       310,864  
Notes payable, long-term portion   $ -     $ -  
Schedule of Notes Payable Debt Discounts

The Company recognized aggregate debt discounts on the notes payable to for the three months ended March 31, 2024, as follows:

 

    March 31,     December 31,  
    2024     2023  
             
Fair value of commitment shares of common stock   $ 73,454     $ 42,175  
Original issue discounts     60,000       24,000  
Legal and brokerage fees     15,000       13,500  
Total debt discounts     148,454       79,675  
Amortization of debt discounts     21,784       26,233  
Unamortized debt discounts   $ 126,670     $ 53,442  
Schedule of Interest Expenses

The Company recognized interest expense for the three months ended March 31, 2024 and 2023, as follows:

 

    March 31,     March 31,  
    2024     2023  
             
Interest on convertible notes, related party   $ 15,123     $ 14,795  
Interest on notes payable, related parties     29,576       5,467  
Interest on notes payable     11,250       37,808  
Amortization of debt discounts, related parties     110       -  
Amortization of debt discounts, common stock     23,555       -  
Amortization of debt discounts     22,365       -  
Total interest expense   $ 101,979     $ 58,070